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Abstract
Dengue is a significant public health problem. There are four dengue virus serotypes 
identified; however, its diagnosis is difficult due to the existence of many viruses, bac-
teria, and parasites producing the same clinical presentation, being present in the same 
geographical area and even producing coinfections. Therefore, determining whether a 
person has, had, or is infected with dengue virus is of great importance. In order to do so, 
direct and indirect laboratory tests have been developed to identify the virus or part of 
its structure that generally detects the antibody response. These techniques are used for 
diagnosis, epidemiological studies, monitoring, assessment and production of vaccines 
and antivirals, etc. They range from the use of cell cultures, animal models, inoculation 
by insects, and serology tests to the use of detection molecular tests and quantification 
of genetic material that are described in this chapter herein, a brief explanation of this 
methodology, its strengths and weaknesses, and its application in the dengue research.
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1. Introduction
Dengue is a dynamic systemic infectious disease and the most important arbovirus world-
wide. Its occurrence has increased in past decades, and it is estimated that 390 million of infec-
tions occurs annually of which 67–136 million manifest clinically with any severity of disease. 
Another study shows that 3.9 billion people are at risk of infection with dengue virus (DENV) 
in 128 countries [1]. Diagnostic tests providing a proper identification of DENV infection by 
any of its four serotypes in symptomatic or asymptomatic cases in the population, and espe-
cially in areas that have more than one arbovirus or another micro-organism (virus, bacteria 
or parasite) producing similar signs and symptoms are the key aspect of any dengue research 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
and surveillance programs [2]. Laboratory tests are based on the detection of the virus, part 
of its genome or structure, or specific result from an infected person or animal as immune 
response. In this chapter, the most used laboratory tests in an arbovirus study focused on 
diagnosis and research of dengue virus (DENV) will be assessed, some comparisons will be 
carried out with other laboratory tests, its features, advantages and disadvantages, and cau-
tions need to be considered during the process.
2. Laboratory test
2.1. Characteristics of diagnostic tests
A diagnostic test intends to identify whether or not a patient has a disease that cannot be 
recognized by signs and symptoms. Ideally, such test must meet the following requirements:
• To achieve high levels of sensitivity and specificity.
• Accurate and precise results.
• To deliver rapid results.
• To be cost effective.
Different studies can be carried out in the dengue research. For example, clinical diagno-
sis diseases, epidemiological studies, clinical assays, viral load tests, vaccines and anti-viral 
assessments, etc. Thus, it is necessary to know the testing capacity to detect the presence or 
absence of the disease (validation of diagnostic tests), so it is very useful to know the following 
diagnostic test indicators (Table 1).
Result of the laboratory test Disease
Positive Negative Total
Positive a (True positive) b (False positive) a + b
Negative c (False Negative) d (True negative) c + d
Total a + c b + d a + b + c + d
Sensitivity: It is the probability that a sick person delivers a positive result in the diagnostic test (a/(a + c)).
Specificity: It is the probability that a person who is not sick delivers a negative results in the diagnostic test (d/(b + d)).
Positive predictive value: It is the probability that a person is sick and gets a positive result in the diagnostic test 
(a/(a + b)).
Negative predictive value: It is the probability that a healthy person gets a negative result in the diagnostic test (d/(c + d)).
Efficiency: It is the probability that a person is properly diagnosed using the diagnostic test ((a + d)/(a + b + c + d)).
Positive likelihood ratio (LR+): It is obtained when dividing sensitivity by the portion of false positives (1 − specificity), 
and it indicates the probability of being sick if the result is positive (Sensitivity/(1 − specificity)).
Negative likelihood ratio (LR−): It is obtained when dividing false negatives (1 − sensitivity) by specificity, and it 
indicates the probability of negative results obtained from a sick person ((1 − Sensitivity)/Specificity).
Table 1. A double-entry table to obtain indicators of diagnostic tests from analyzing a sample showing all possible results.
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The sensitivity and specificity have distinctive features of diagnostic tests, they are not com-
promised by the prevalence of the disease, and they are inversely proportional. If a study in 
which the majority of people are suffering from this disease is carried out, a high sensitivity 
test is needed in order to identify the highest number of true positive and the lowest number 
of false negative. However, it may increase the number of false positive. If you want to obtain 
a good disease diagnosis, a high specificity test must be used to detect the highest number 
of true negative. Here, the false positive will also be low. Moreover, positive and negative 
predictive values of the diagnostic tests are affected by the prevalence of the disease in the 
study population. The likelihood ratio (LR) that is independent of prevalence is used when 
the laboratory tests do not present dichotomous results but cut-off value. This is another way 
of assessing the accuracy. According to the results, the test can be classified into adequate 
(LR+ ≥ 10 to LR− ≤ 0.1), moderate (LR+ ≥ 5 < 10 to LR− > 0.1 ≤ 0.2), scarce (LR+ ≥ 2 < 5 to 
LR− > 0.2 ≤ 0.5) and insignificant (LR+ ≥ 1 < 2 to LR− > 0.5 < 1). Not only one but also many tests 
can be used to diagnose dengue in the epidemiological studies. It can be done sequentially 
or in parallel. For example, when performing a test with two sequential tests, all positive 
people need to be assessed with a second test upfront, and this will cause the reduction of net 
sensitivity and a net specificity enhancement obtained from both tests. It will be considered 
as positive if their tests are positive in all tests. Likewise, the negative ones will have negative 
results in the confirmatory test. On the other hand, if two simultaneous tests are used, a net 
sensitivity is gained, while a net specificity is reduced. This is different when tests are done 
independently. Negative is considered people whose negative results were in all tests and 
positive the ones whose positive results were in at least one of the tests [3, 4].
2.2. Biological samples for dengue studies
The type of sample taken in the right moment, storage and transport to the laboratory to be 
processed, and the appropriate documentation plays a key role to obtain results because if 
there is a change of sample quality, this can reduce antibody titers, viruses or genetic mate-
rial resulting in lower titers or concentrations from the real ones in quantitative tests or false 
negative results in quantitative or qualitative tests.
The most used samples to diagnose and to search about dengue are whole blood, serum, 
plasma, and human organs like spleen, liver, and heads of mosquitoes, pools of mosquitoes, 
brains of mice, serum samples saturated with filter paper, etc. The serum samples that will 
be processed for virus isolation and/or polymerase chain reaction tests and fluorescent focus 
assay to quantify the virus in serum are collected in tubes without anticoagulants. They must 
be taken within 1–5 days after the onset of symptoms, to detect the antigen (NS1 protein), 
within 1–6 days to detect IgM antibodies for enzyme-linked immunosorbent assay (ELISA) 
or a rapid test after day 5 of starting the symptoms, within 1–5 to detect IgG using matched 
serums to assess seroconversion for ELISA, neutralization test or hemagglutination inhibition 
used in acute serums, and convalescent serums after day 15. In the case of liver, spleen, kid-
ney or nodes samples, a sample is immediately taken after the person’s death or the animal in 
experiment. The samples must be taken to the laboratory as soon as possible and preferably 
dealt with in dry ice or liquid nitrogen [5, 6].
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2.3. Primary and secondary dengue infections and dengue diagnostic
Although most infections are asymptomatic or subclinical, a set of symptoms starts after a 
dengue infection elapses the 4–10-day incubation period. A four-fold increase of the IgG anti-
body titers in matched serums measured by ELISA IgG test or hemagglutination inhibition 
indicates recent flavivirus infection. When people are infected with the virus on the first time, 
dengue infections are known as a primary infection in which a viral load and the relevant 
antibody formation (IgM, IgG and IgA) are triggered. In a primary infection, the titer of IgM is 
generally much higher and more specific than in a secondary infection. Some studies consider 
that an infection is primary if the IgM/IgG relation is higher than 1.2 with diluted samples at 
1:100 or 1.4 using diluted serum at 1:20. When people are previously exposed to any sero-
type or flavivirus, or even after a vaccine (i.e., yellow fever vaccine), dengue infections are 
secondary and the IgM/IgG relation is lower than 1.2 or 1.4. In secondary infections, the IgG 
is detected in the highest levels and even on the acute phase. It remains higher for 10 months 
and even lifelong in order to consider a person being infected with dengue virus (DENV), the 
following laboratory test interpretations need to be followed:
• When a sample taken from the acute phase is positive for dengue due to the PCR test, viral 
isolation, and IgM serocoversion in matched serum samples, the IgG seroconversion in 
matched serum samples or the fourfold increase of IgG titer is considered confirmed cases.
• When a positive IgM occurs in a single serum sample or a positive IgG in a single sample 
with hemagglutination inhibition titer is the same or higher than 1:1280, it is considered a 
suggestive case [5–8].
2.4. Laboratory test
The laboratory tests can be interchangeably used in different researches, both basic and 
applied ones. We can classify them into direct methods that allow virus detection or part of its 
structure and indirect methods which identify a reaction produced by the presence of DENV 
in the organism.
2.4.1. Direct detection methods
2.4.1.1. Viral RNA extraction
The genetic material extraction has a key role for PCR tests so that the quality of a product 
extracted can vary depending on the type of sample being used, and the extraction method 
applied will directly affect the test sensitivity. The dengue RNA can be recovered from serum, 
blood, urine, plasma samples and other organs. However, the viral load in blood is much 
higher (7.9 × 102–1.9 × 105 PFU/mL) in comparison with saliva and urine samples (1 × 101–5 × 101 
PFU/mL). The RNA extraction can be done by guanidine thiocyanate and trizol methods and 
by the use of commercial kits like Qiagen kit (QIAamp® RNA Viral mini kit), etc. RNA extrac-
tion techniques in serum/plasma samples from patients using QIAamp® UltraSens Virus Kit 
(Qiagen Inc., Valencia, USA) were compared to the modified Chomczynski-Sacchi extraction 
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technique in order to extract plasma RNA so that the original technique is used for cell or 
tissue samples being more cost effective than the kit commercial one. It was found that 34 
samples out of 47 were positive by using the Chomczynski-Sacchi method, and the remaining 
27 samples were positive by using the kit commercial method [8–10].
2.4.1.2. Reverse transcription polymerase chain reaction (RT-PCR)
The RT-PCR techniques and their different variants are converted into one of the main tools 
for diagnosing DENV and other arbovirosis. Less time to process the results, being able to 
identify the circulating serotypes of the virus, presenting the highest sensitivity and specific-
ity levels are among its advantages. This type of test has the benefit of obtaining rapid results 
while identifying circulating serotypes of dengue. The RT-PCR technique is the extraction of 
a RNA sample followed by a reverse transcription process, the actual PCR (nested or not), and 
the last screening in gel obtaining a qualitative result. The technique developed by Lanciotti 
and his collaborators or the variant developed by Harris and his collaborators, which have 
been used for many years, is recommended by the Pan American Health Organization 
(PAHO/OPS). The technique developed by Lanciotti starts with converting RNA into DNA by 
using a reverse transcriptase enzyme. Then, the PCR is carried out when primers are used to 
amplify prM genes and C virus areas to continue with a specific primer-nested PCR for each 
virus serotype. Harris and his collaborators developed a multiplex RT-PCR from Lanciotti 
and his collaborators’ method that uses five pairs of primers (four specific pairs for serotypes 
and one pair of the region of the capsid gene). There are many different variants in this tech-
nique having different sensitivity levels that are used in research laboratories. One of the main 
disadvantages is the possible existence of a false positive due to the contamination produced 
by amplicons during the reverse transcription of the genetic material, and it is necessary to 
consider that a negative result in these tests does not rule out DENV infection or other arbo-
viruses, and the analysis must be complemented by serological findings (Figure 1) [9, 11].
2.4.1.3. RT-PCR multiplex to DENV and different microorganism identifications
Chikungunya (CHIKV), Zika (ZIKV), Yellow Fever (YFV) and DENV are arboviruses with 
the highest prevalence in the American continent. They are transmitted by the same vec-
tor Aedes aegypti y Aedes albopictus facilitating its cocirculation in some areas of the region. 
Because of these arboviruses, the affected patients develop similar symptoms but its clinical 
management and its possible results as the aftermath of the disease, and mortality rates are 
different. They can even produce coinfection with other microorganisms making a proper 
identification necessary in an early stage of the disease (acute phase). There are commercial 
and standardized testing in a laboratory allowing qualitative identification of DENV, ZIKV, 
and CHIKV in serum, plasma, and even some urine samples [12]. Other commercial testing 
like FilmArray Global fever panel has the capacity of detecting genetic material in viruses, 
bacteria and protozoa (nine viruses like YFV, DENV, ZIKV, WNV, CHIKV, among others, six 
bacteria and four protozoa) in whole blood (EDTA), with automated equipment. A study to 
determine a detection limit for microorganisms using FilmArray Global fever panel found 
the following results for DENV like DENV-1 (Hawaii) 2.7 × 101, DENV-2 (New Guinea C) 
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3.6 × 101, DENV-3 (H87) 1.6 × 103 and DENV-4 (H241) 7.6 × 101. The main advantage of this test 
is time reduction to obtain results (about an hour), discriminating the amount of pathogens, 
and minimizing cross-contamination problems so that all reactions are carried out among a 
closed system. The cost of the product and a machine analyzing only a sample at a time is 
within its limiting [13].
2.4.1.4. Real-time PCR
It uses conventional RT-PCR principles, and it combines with fluorochromes like SYBR Green 
or TaqMan probes with fluorochromes capable of producing proportional fluorescence to the 
DNA copy samples. The strengths of this test are the same as the conventional RT-PCR, it also 
reduces time when releasing the results as well as the cross-contamination risk post PCR, the 
levels of sensitivity and specificity are higher than the conventional RT-PCR, and overall it 
allows quantifying the genetic material. There are different commercial kits in the market to 
diagnose DENV, and its sensitivity and specificity levels vary when they are compared among 
them [14, 15]. The CDC elaborated a real time RT-PCR in order to diagnose four serotypes 
in serum or human plasma samples using an ABI 7500 FAST DX thermo-cycler of Applied 
Biosystems and hydrolysis dual-marker TaqMan probes, and it is the first RT-PCR approved 
by Food and Drug Administration (FDA) to detect DENV [16].
Figure 1. Reverse transcriptase semi-nested reactions, using primers targeted to the C/PrM genomic region as described 
by Lanciotti et al. (a photo taken on April 24, 2018 in the molecular biology laboratory with the authorization of the 
U.S. Naval Medical Research Unit Six (NAMRU-6).
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2.4.1.5. Viral isolation in cell lines
Viral isolation in cell cultures or mosquitoes followed by the virus detection using indirect 
immunofluorescence is considered as gold standard [8, 17]. In order to carry out the DENV 
viral isolation and as a general rule to any virus, it is necessary to consider the following:
• To know the isolated virus (virus characteristics, replication, transmission mechanism, etc.)
• To know which biosafety level a virus can be performed. In the case of DENV, biosafety 
level 2 is needed [18].
• To determine which cell line to use and to be able to isolate the virus, it is essential to iden-
tify the most sensitive cell line from mosquitoes and mammals, and its use for the isolation 
and DENV propagation, being the most sensitive cell lines of mosquitoes as follows:
• C6/36: they are easy cell propagation, highly sensitive to DENV infection, and culti-
vated at 28°C that are obtained from salivary glands of Aedes albopictus.
• C6/36 HT (hot temperature): they can be spread at 34°C and have a bigger sensitivity 
to detect DENV. This cell line maintains its high sensitivity only for some weeks due 
to its higher temperatures, so some researchers suggest adapting at 34°C, a C6/36 cell 
line growing at 28°C, and using an alternative method.
• TRAS-284-SF cell has the main benefit of not requiring the use of fetal bovine serum 
(FBS) as a culture medium, and it presents a higher sensitivity to the DENV isolation 
[6, 9, 17].
• Knowing the viral isolation technique that provides better results to isolation and virus 
propagation. The standard method is based on the virus propagation in a sensitive cell 
line for inoculating a previous diluted sample in a cell culture medium. After the infection 
process, the cultures are placed on incubation for the binding of the virus to the cell; sub-
sequentially, it is placed on a means of maintenance with the essential nutrients to main-
tain the live cultures for a period of time that can be 13–15 days. Then, the infected cells 
are recovered, and the virus presence is determined by an immunofluorescence process, 
ELISA, molecular techniques, and others. Bottles, tubes, 6–96 well culture plates, and oth-
ers are used in order to sustain the binding to cell cultures. A modified shell vial technique 
allows the recovery of a higher number of YFV, SLV, WNV, ILHV, GCV, OROV, MAYV and 
DENV isolations. This technique follows the same steps as a standard method, but after 
inoculating cells, the cultures are centrifuged to velocities between 1800 and 2200 rpm. This 
technique can also be used to isolate DENV coinfections. However, it seems not to have 
good results for VEE isolation [19–22].
• The sample type to be used. The sample type to be used and its proper preservation until 
the processing time are extremely important to isolate a virus. The most used dilutions to a 
viral isolation vary from 1:5 to 1:20. A very concentrated dilution of the sample could gen-
erate a toxic effect in the cells. On the other hand, a much diluted sample could cause the 
inability of isolating the virus because of having a low concentration virus in the inoculum 
[19, 21].
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2.4.1.6. Plaque assay
It is the most used test to determine viral vaccine titers so that it quantifies the virus to infect 
cells. It is based on the infection of a cell monolayer with different virus dilutions to evaluate. 
After an incubation period, the viral infection results in lytic plaques. If they are colored, they 
are displayed as holes in the cell monolayer. Each plaque corresponds with an infectious virus. 
One of the main disadvantages of this technique is that it can only use viruses being able to pro-
duce a cytopathic effect. Another one is that all native strains of DENV are not always capable 
of producing well-defined plaques, and the viral titers can vary depending on the cell line used. 
For a dengue virus case, the most used cell lines are VERO and BHK-21 (Figure 2) [5, 6, 23].
2.4.1.7. Fluorescent focus assay
It is a combination of plaque assay and immunofluorescence. Viruses are inoculated in dif-
ferent dilutions in the cell line, then a cell incubation period is fixed to plaques with any 
organic solvent, and an immunofluorescence is carried out. Positive cells are observed with 
fluorescent foci that can be counted. One of its advantages is to reduce the incubation period 
Figure 2. Plaque assay titration for DENV-2 using VERO-76 cells and a semi-solid method (a photo taken on March 
2017, in the Virology and Molecular Biology Laboratory of the Faculty of Biological Sciences at National University of 
San Marcos, Peru).
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in order to obtain the results in comparison with plaque assay. It allows processing a bigger 
number of samples so that it can be adapted to use 96-well culture plates in comparison with 
the 24-well plates which are used in the plaque assay. Another advantage is to allow the use 
of C6/36 cells that are highly sensitive to detect dengue virus, and they cannot be used for the 
plaque assay as they do not form lytic plaques (Figure 3) [23].
2.4.1.8. Viral isolation in nursing mice
Suckling mice were greatly used because of their easy reproduction and handling to isolate 
virus as well as the antigen production. About 1–3 neonatal mice and an intracranial inocula-
tion are carried out. Then, a 21-day daily checking to observe the occurrence of neuromotor 
symptoms is needed. This technique is starting to cease to use due to a great variety of cell 
cultures that allow good sensitivity levels in DENV detection. This is why the Institutional 
Animal Care Committee and IACUC Committee recommend reducing this activity. One of 
the most common practices to carry out euthanasia on suckling mice is using a CO2 camera. When using this technique, it is necessary to make sure such mice are dead as they are very 
resilient to lacking of oxygen so it is advisable to continue with other euthanasia techniques 
like cervical dislocation, decapitation, etc. [6, 9, 24].
2.4.1.9. Inoculation in mosquitoes
The mosquitoes like Aedes genus can be used for dengue virus isolation when infection and 
disease transmission studies are carried out. The intracerebral and intrathoracic inoculations 
are used for mosquitoes which are immobilized at low temperatures. The mosquito infection 
technique is to feed them directly with the dengue-infected patient blood in the acute phase of 
the disease. The mosquitoes of the Toxorhynchites genus, which are not blood-feeding insects, 
can be used for the four-serotype dengue isolation, Japanese encephalitis and encephalitis 
of San Luis are more susceptible than cell culture isolation of dengue virus as well as the 
Drosophila melanogaster that can be inoculated by micro injection in the abdomen, and it could 
reach higher titers using less time in comparison with the Aedes aegypti inoculation [6, 25, 26].
Figure 3. Fluorescent focus assay for DENV-2 using the C6/36 (A) and VERO-76 cells (B). The indirect immunofluorescence 
performed to visualize the foci was carried out on the fifth day of incubation, using the fluorescein isothiocyanate (FITC) 
conjugate (a photo taken on March 15, 2016 in the Serology laboratory with the authorization of the U.S. Naval Medical 
Research Unit Six (NAMRU-6)).
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2.4.1.10. Automated equipment for virus counting
There are redesigned flow cytometers to quantify a virus in solutions like The ViroCyt® Virus 
Counter (VC) 2100 (ViroCyt, Boulder, CO, USA) using a specific fluorescent dye for the enve-
lope proteins and the other one for the nucleic acids that allows recognizing viral particles 
having both components in its structure. Then, it eliminates anything that represents one type 
of fluorescent [27].
2.4.1.11. Enzyme-linked immunosorbent assay (ELISA) for NS1
The NS1 nonstructural protein is produced during dengue infection and accumulated in 
higher concentrations in the human serum (up to 50 μg/ml) being detected during the acute 
phase (day 0–6) after the symptoms in primary and secondary infection start. Some studies 
have reported a correlation between elevated NS1 protein levels with hemorrhagic dengue 
cases, and even this technique seems to be effective to detect DENV in the vector. When 
evaluating three of these commercial tests from different manufacturers with human serum 
samples, it is found sensitivity between 85.5 and 95.9% and specificity between 95.0 and 100% 
using the viral isolation as a reference test [28].
2.4.2. Indirect methods
2.4.2.1. IgM ELISA
IgM can be detected on 50% infected people within 3–5 days and after the symptoms onset, 
and it reaches approximately to 80% infected people on day 5 and to 99% infected people 
on day 10 reaching maximum levels in humans at the 2 weeks to falter until they are not 
detected on 2–3 months. An indirect capture ELISA is usually used for detecting IgM, and it 
allows increasing sensitivity of the test in detecting antibodies. However, IgM antibodies are 
not specific, and they could present a cross-reaction with other flavivirus like YFV, ZIKV, etc. 
Besides, some particular test characteristics could alter the result of the test as the rheumatoid 
factor depending on IgM ELISA type causes false positives [5, 7–9].
2.4.2.2. IgG ELISA
The IgG is detected with low titers when ending the first week of the onset symptoms in 
humans, and they could even be detected for a lifelong. The tests to detect an IgG using the 
virus bind to a plate in a smooth antigen way (protein cocktail) usually present a low specific-
ity so that there is a cross-reaction with other viruses from the same genus due to the proteins 
found in the antigen, and this test cannot be used to determine the infectious dengue serotype 
but it can present a higher sensitivity than the hemagglutination inhibition test. The ELISA 
is also used for studying how different IgG sub-classes react in a dengue infection [5, 7–9].
2.4.2.3. IgG inhibition ELISA tests
It can be used to differentiate a primary infection and a secondary infection from dengue 
replacing an hemagglutination inhibition test using a percentage of inhibition higher or the 
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same as 50% as a positivity criterion. In case of having only a serum sample, a primary infec-
tion is considered when the antibody IgG titer is ≤20, and a secondary infection is considered 
if the antibody titer is ≥1280. In both cases, the sample must be collected on 5–7 days. If there 
are paired samples, a primary infection is considered when the seroconversion in antibody 
titers from the acute and convalescent phase occurs, and a secondary infection is considered 
when the antibody titers increase four times or more between the acute and convalescent 
phase, or in both serums [6].
2.4.2.4. IgA ELISA test
It was used in some studies to identify the infected people in an early stage of dengue infection. 
Thus, it was found 100% of sensitivity in people with secondary dengue infection after symp-
tom onset-day 1. However, the results were not very favorable for primary infections [29].
2.4.3. Neutralization test
2.4.3.1. Plaque reduction neutralization test (PRNT)
This test is considered the gold standard to detect neutralizing IgG antibodies because they 
have high sensitivity but can have a cross-reaction among members of flavivirus group. It is 
based on the binding of antibodies present in the sample which contains a known virus load 
(working dilution). The mixture of both is incubated and inoculated in a cell line until forming 
lytic plaques that are observed when coloring the cell monolayer. All samples neutralizing 
and avoiding the forming of certain number of plaques (being the most commonly used for 
50–90% reduction) are with the presence of neutralizing antibodies indicating exposure to 
dengue. Using 1 in 30 diluted serum samples allowed discriminating between DENV-1 and 
DENV-2 serotypes in collected serum in Cuba, before and after the 1981 epidemic caused by 
DENV-2. There are many different variants of a PRNT test that could produce a variation in 
the results when being compared with using different used reduction rates, different PRNT 
methods (solid or semi-solid), and different cell lines. The most used for dengue are VERO 
cells that are recommended by World Health Organization (WHO), and BHK-21 that are 
used by other laboratories like Pedro Kouri Institute of Cuba. The use of different genotypes 
can alter the antibody titer results. Kochel et al. [30] evaluated Peruvian samples infected 
with DENV-2 American genotype. Antibody titers were found in higher levels when using 
the same genotype rather than using the Asian genotype. PRNT can be used to differentiate 
dengue infection to yellow fever infection. It has been found that the lowest serum dilution 
capable of distinguishing between both infections is 1 in 5. In a dengue secondary infection, 
PRNT can have a cross-reaction with other serotypes. In infected populations with sequen-
tially different serotypes of dengue, the highest antibody titer pertains to the first infection 
(the “original antigenic” sin phenomenon) (Figure 4) [5–7, 30–32].
2.4.3.2. Focus reduction neutralization test (FRNT)
It combines the PRNT test with immunofluorescence or ELISA to count fluorescent foci or 
spots and calculate their reduction rate in the samples. Among its advantages, this allows 
reducing the days to obtain the results and undertaking studies with native strains so that 
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some of them produce tenuous plates that are difficult to count but they make easier to detect 
fluorescent foci. Moreover, more sensitive lines can be used to detect dengue, not forming 
C6/36 plates, and they can be adapted to plates with a higher number of wells enabling to pro-
cess a higher number of samples and saving materials. And, fluorescent foci can be counted 
with an ultraviolet light microscope or using computerized readers capable of reading fluo-
rescent foci and reducing time to obtain results [33, 34].
2.4.3.3. Microneutralization-ELISA
It is a variable in the PRNT test and uses the same immunological basis with the advan-
tage of being worked on 96-well plates different from the PRNT that generally uses 24-well 
plates. This allows saving materials and handling a higher number of samples. This technique 
is used to detect the presence of neutralizing antibodies in the sample which is mixing the 
patient’s sample that is previously inactivated in different dilutions with the dengue virus 
serotype to be evaluated, once the antigen-antibody binding is inoculated in the specified cell 
line as VERO-76 cells. If there were neutralizing antibodies in the sample, these ones would 
block the entry from the virus to the cell and would not produce the infection. The presence 
of the virus in the cell is revealed by an ELISA procedure. Samples exposing the color change 
in a substrate will be considered as negatives to an IgG antibody against the dengue serotype 
under study, and the samples that do not produce color change in the substrate will be posi-
tive for the presence of IgG antibodies (Figure 5). When this technique was evaluated with 
serum samples from patients with primary infection, the results were very similar to the ones 
in PRNT. However, the result correlation was very poor in comparison with this technique 
using samples from patients with secondary infections [35].
2.4.3.4. Immunofluorescence test
This test can be direct or indirect, and it is the most commonly used to identify the infected 
cells deriving from cell lines, salivary glands of mosquitoes, etc. It is based on the binding of 
Figure 4. Plaque reduction neutralization test for DENV-2 using BHK-21 clone 15 cells. Dilutions from 1:20 to 1: 160 were 
used. Sample A and C do not present antibodies against the DENV2, and sample B is positive up to a dilution greater 
than 1: 160 (a photo taken on March 23, 2012 in the PRNT laboratory with the authorization of the U.S. Naval Medical 
Research Unit Six (NAMRU-6)).
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the actual virus to a sample that can be infected cells with a dengue virus antibody joined to 
a fluorescent marker named conjugated (direct immunofluorescence). One of the most used 
fluorochromes for this technique is the fluorescein isothiocyanate (FITC). First, a specific anti-
body is to bind to a specific virus in the indirect immunofluorescence (the used antibody can 
be monoclonal or polyclonal, and it is bind to a conjugated). Observing the samples under 
ultraviolet light of the microscope, the fluorescent cells indicate the presence of the virus in 
the cell. This test is quite cost effective, and its sensibility and specificity can vary depending 
on the antibody quality used for virus identification. The polyclone antibodies are produced 
by sensitizing mice with the specific virus to detect. If an inactivated and structurally com-
plete virus is used, the mice will produce antibodies against virus proteins resulting in a high 
cross-reaction within the virus of the same genome as it is the case of DENV, YFV, ZIKV, SLV, 
WNV, etc. Monoclonal antibodies produced in hybridomas can eliminate or reduce cross-
reactions (cell lines are able to produce antibodies against one or various virus epitopes) with 
bigger specificity. There are antibodies produced in hybridomas capable of identifying and 
differentiating flavivirus group, a general dengue virus (dengue complex), and to each den-
gue virus serotype (Figure 6) [5, 6].
2.4.3.5. Rapid tests
There are rapid tests based on lateral flow chromatographic immune assays produced by 
different laboratories. Proteins such as NS1, IgM, IgG in serum, blood or plasma samples can 
be detected through these tests, and they can simultaneously identify antibodies or proteins 
produced by ZIKV, DENV, and CHIKV. Assessing four rapid tests for NS1, its sensibility was 
in 71.9–79.1% range and its specificity in 95–100% antibodies compared to the viral isolation. 
These tests have the benefit of being cost effective, not requiring qualified personnel to be 
Figure 5. Enzyme-linked immunosorbent assay-format microneutralization test for DENV-2. The samples were 
inoculated in triplicate in VERO-76 cells using dilutions from 1:40 to 1: 320, and the ELISA test was performed on day 
5 post inoculation (a photo taken on April 24, 2018 in the serology laboratory with the authorization of the U.S. Naval 
Medical Research Unit Six (NAMRU-6)).
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done nor using sophisticated equipment. Within its limitations, it is not possible to identify 
the circulating serotype in a virus, the band intensity is not related to the antibody titers nor 
the actual NS1 antigen in the sample, cross-reactions with other flavivirus are common, a 
negative result in these tests does not exclude that the patient has been exposed to the virus, 
and some samples present high titers of rheumatoid factor affecting the results. The positive 
samples for these results should be verified with other alternative methods [28].
2.5. The animal models for dengue virus
Studies to evaluate antivirals against dengue, vaccines, plant extracts, etc. mainly use the 
mouse model and nonhuman primates (NHPs). However, each of them presents a series of 
constraints that impair research developments. The infections of the mouse model are used for 
pre-clinical development of vaccines. In this model, a neurotropic disease can occur; however, 
this does not usually happen in humans. Some mice like C57BL/6, BALB/c and A/J enable viral 
replication, but A/J and BALB/c mice develop paralysis. Some studies show that C57BL/6 mice 
can have hemorrhages when being infected with a DENV2 strain 16681 using a virus with a 
titer of 3 × 109 PFU/mL. Moreover, an infection and endothelial cell damage as well as hemor-
rhages in tissues can occur without showing signs of disease. The DENV replication in mice is 
low, but suckling mice inoculated by an intracranial via at high DENV doses can induce neu-
rological illnesses and paralysis that is used to measure the effectiveness of the vaccines. They 
can also be used to test a virus neurovirulence or an attenuation to produce vaccines. NHPs are 
used to research an immune reaction against DENV, an evaluation of candidates’ vaccines, a 
replication kinetic, etc. This model has a major constraint because it does not produce signs of 
clinical disease. Nonetheless, DENV can infect some cells in the body. An inoculation with 105 
PFU DENV concentrations enables a lower viral replication in humans, and it is restricted to 
lymphoid-rich tissues producing lymphadenopathy, lymphocytosis, and leukopenia. Rhesus 
macaques can produce antibodies against DENV and a similar viral load to the humans. The 
inoculation of high titer DENV via intravenous in rhesus macaques can produce hemorrhage. 
The physiology of pigs is similar to the human one. Yucatan miniature swine models present 
Figure 6. Indirect immunofluorescence test performed on C6/36 cells. In (A), uninfected red cells are observed and in (B), 
infected green cells are observed (a photo taken on April 24, 2018 in the serology laboratory with the authorization of the 
U.S. Naval Medical Research Unit Six authorization (NAMRU-6)).
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an immunological and physiological result similar to the human ones. It is known that it is sus-
ceptible to a flavivirus such as the Japanese encephalitis, YFV, and Murray valley encephalitis. 
Studies about infected porcine models administered subcutaneously with DENV-1 (107 PFU) 
resulting to developed viremia, and IgM and IgG antibodies without symptoms are carried 
out. The secondary infection with the same serotype produced extensive macular and papular 
rashes similar to the ones affecting humans. When infecting the swine model with a DENV-1 
intravenous line, a rash skin and dermal edemas appeared on the animal [36, 37].
2.6. The future of laboratory tests and its connection with dengue studies
Throughout a dengue research, the use of laboratory tests play a fundamental role in identify-
ing the virus (serotype, genotype and lineage), its genetic material, viral proteins, the pres-
ence of antibodies against the virus or assessing the patient’s condition, and for instance, 
hematocrit, platelet count, white blood cell count, blood count, etc. together with patient’s 
signs and symptoms and some epidemiological criteria, it allows categorizing the disease 
for dengue with or without warning signs or severe dengue. This classification assists in 
deciding what therapy to choose and preventing from a severe dengue development. Besides 
the above mentioned techniques in this chapter, there are laboratory techniques which are 
not commonly used at present because they are expensive and/or they require sophisticated 
equipment but they could be used for DENV studies. Among them, there is the transmission 
electron microscopy (TEM) which is a gold standard technique for the absolute quantifica-
tion of particles. However, it does not allow differentiating an infectious virus from a non-
infectious one. The high performance liquid chromatography (HPLC) where the virus load 
is quantified through the UV analysis of fractions produced during HPLC. Flow cytometry 
(FC) can be used to quantify viral proteins being present on the surface of the infected cells. 
The next-generation whole genome sequencing is the most advanced sequencing technology 
which allows learning the complete and detailed genome sequence of an organism in a short 
period of time (days), though its cost is still quite higher to some researches [27, 38].
Dengue researches in the future will try to respond to different problems, needs, and gaps in 
knowledge like:
The production and improvement of the vaccine against DENV like Dengvaxia® (CYD-TDV), 
produced by Sanofi Pasteur, is a prophylactic, tetravalent, live attenuated recombinant viral 
vaccine which uses a 3-dose vaccination schedule, and it is recommended for people ranged 
from 9 to 45, or 9 to 60 year old (depending on the license) [39]. Nonetheless, it is necessary 
to continue with searches to develop a vaccine which can be used from the first year of life 
enabling to achieve the maximum immunity with a single dose and can be used in different 
endemic areas obtaining the same immunity level regardless the disease prevalence.
Today, it is acknowledged that the immunity against dengue after a natural infection can be 
for a lifetime [5]; however, some studies indicate that a dengue reinfection may occur under 
certain conditions [40].
The relation between chronic diseases and dengue has been studied as risk factors in order 
to determine the severity of dengue disease in individuals. In recent decades, the increase of 
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chronic diseases and being one of the main causes of death in today’s world require to continue 
and deepen the study of these diseases as well as its association with the dengue disease [5].
In endemic areas, dengue studies in blood banking are essential especially in epidemic out-
breaks so that when there is a large amount of asymptomatic DENV, the virus may be trans-
mitted through blood transfusions [41].
Individuals with inapparent dengue virus infection are considered dead-end hosts for trans-
mission because they do not present high enough levels of viremia to infect mosquitoes; 
nonetheless, some studies show that asymptomatic people for dengue can transmit the virus 
to mosquitoes when bitten, although having a lower average of viremia, increasing the risk 
of disease spread in different areas [42]. Therefore, it is important to carry out studies with 
individuals presenting inapparent dengue virus infections aimed at breaking the transmis-
sion cycle and avoiding disease spread.
Wildlife mammals with genetic material and antibody against DENV like bats have been 
found, but their participation in the transmission cycle have not been approved yet [43].
Because of not having found an animal model able to replicate the dengue disease, it is neces-
sary to continue searching for different animal models which can support the study of this 
disease so that the use of humanized mice becomes an attractive area of research [36, 37].
The development of new drugs and the vegetal compound assessment with antiviral activity 
against DENV are needed because there is no specific treatment for this disease yet.
The use of mathematical models to predict the pace of dengue spread based on clinical data 
and laboratory results may support the prognosis of this disease.
DENV has a type of RNA genome, with a dependent RNA polymerase without a corrective 
activity being able to accumulate genetic material changes leading to a false positive increase 
in PCR tests [11]. Thus, it is required to evaluate the necessity of primer redesigning which 
allows detecting a larger amount of DENV circulating strains worldwide as well as its stan-
dardization and assessment.
DENV coinfections along with other microorganisms circulating in the same endemic areas 
like DENV/plasmodium Sp. may be frequent depending on the disease prevalence in the 
area, especially if they are transmitted by the same vector in cases like DENV, CHIKV and 
ZIKV. Some studies have shown infections of Aedes aegypti with MAYV causing a concern 
about a possible natural transmission of such disease in urban areas [22, 44].
3. Conclusion(s)
Dengue is still a leading public health problem. The diagnostic tests must improve and be 
standardized in all research and diagnostic laboratories with the use of technology. This will 
allow having comparable results in different studies and reference centers that contribute 
to the knowledge development needed to understand transmission mechanisms and DENV 
propagation and setting preventive and appropriate control measures as well as developing 
new vaccines and antivirals helping to control this disease.
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